PALB2 and cancer: These findings confirm that BETi, in combination with PARPi, results in synthetic growth inhibitory activity in PALB2 deficient cancer cells through induction of DNA damage accumulation resulting from the simultaneous blockade of compensating DNA repair processes [24].